Skip to main content

Advertisement

Table 2 Optical coherence tomography measurements and visual acuity over the course of medication changes

From: Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series

  Median (interquartile range) Wilcoxon p value Friedman’s p value
Central macular thickness (CMT), μm <0.001
 OCT 1 317 (259.5–362.5)
 OCT 2 285 (228–337) 0.034a
 OCT 3 296 (231.5–409) 0.080b
 OCT 4 283 (229.5–374.5) 0.016c
Total fluid volumed, mm3 <0.001
 OCT 1 2.56 (1.05–4.47)   
 OCT 2 2.44 (1.03–4.54) 0.080a  
 OCT 3 3.18 (0.96–4.39) 0.019b  
 OCT 4 2.11 (0.82–3.57) 0.016c  
Subretinal fluid (SRF), mm3 <0.001
 OCT 1 0.16 (0.01–0.88)   
 OCT 2 0.19 (0.006–0.59) 0.018a  
 OCT 3 0.34 (0.04–1.42) 0.057b  
 OCT 4 0.11 (0–0.36) 0.003c  
Intraretinal fluid (IRF), mm3 <0.001
 OCT 1 0.007 (0–0.44)   
 OCT 2 0.002 (0–0.11) 0.102a  
 OCT 3 0.12 (0–0.78) 0.019b  
 OCT 4 0.0005 (0–0.44) 0.336c  
Pigment epithelial detachment (PED), mm3 <0.001
 OCT 1 2.00 (0.64–3.27)
 OCT 2 1.64 (0.71–3.40) 0.307a
 OCT 3 1.95 (0.65–2.79) 0.238b
 OCT 4 1.76 (0.53–2.55) 0.179c
Visual acuity (VA), logMARe <0.001
 OCT 1 0.30 (0.18–0.48)
 OCT 2 0.30 (0.18–0.44) 0.175a
 OCT 3 0.30 (0.14–0.57) 0.292b
 OCT 4 0.30 (0.18–0.60) 0.104c
  1. Treatment response of patients with chronic neovascular age-related macular degeneration switched from bevacizumab or ranibizumab to aflibercept and then back to bevacizumab or ranibizumab
  2. OCT 1 represents the last OCT on bevacizumab or ranibizumab prior to transition to aflibercept. OCT 2 represents the first OCT after switching to aflibercept. OCT 3 indicates the last OCT on aflibercept before transition back to bevacizumab or ranibizumab. OCT 4 represents the first OCT after switching back to bevacizumab or ranibizumab
  3. aComparing response from bevacizumab or ranibizumab (OCT 1) to aflibercept (OCT 2)
  4. bComparing progression while on aflibercept (OCT 2 and OCT 3)
  5. cComparing response back to bevacizumab or ranibizumab (OCT 4) from aflibercept (OCT 3)
  6. dSummation of subretinal fluid, intraretinal fluid, and pigment epithelial detachments
  7. eLogarithm of minimum angle of resolution